Want to see SE:CARA full AI Analyst Report?
CARA Stock Chart & Stats
kr29.00
-kr0.28(-1.22%)
At close: 4:00 PM EST
kr29.00
-kr0.28(-1.22%)
Day’s Range― - ―
52-Week Rangekr21.70 - kr29.45
Previous CloseN/A
Volume42.56K
Average Volume (3M)118.19K
Market Cap
kr1.79B
Enterprise Valuekr1.50K
Total Cash (Recent Filing)kr51.43M
Total Debt (Recent Filing)kr28.66M
Price to Earnings (P/E)42.1
Beta0.16
Next Earnings
Oct 15, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield15.83%
Share Statistics
EPS (TTM)0.62
Shares Outstanding70,324,780
10 Day Avg. Volume93,461
30 Day Avg. Volume118,190
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)2.36
Price to Sales (P/S)5.54
P/FCF Ratio-4.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.34
Revenue Forecast (FY)kr413.95M
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityThe return to positive earnings marks a meaningful recovery in operating performance after the loss-making 2023–2024 period. Positive EBITDA and net margins improve internal funding capacity, support product investment, and provide a stronger base for sustaining the healthcare software business.
Very Low LeverageMinimal leverage materially reduces financial risk and preserves flexibility for Carasent to invest in software development, customer implementation, or expansion without relying heavily on creditors. A well-capitalized balance sheet also improves resilience if healthcare-provider spending becomes less predictable.
Improving Cash GenerationPositive operating and free cash flow, combined with strong recent FCF growth, indicates that the recovering earnings base is beginning to translate into usable cash. This supports reinvestment, strengthens liquidity, and gives Carasent more self-funded capacity to develop and deploy healthcare software.
Bears Say
Decelerating Revenue GrowthCurrent revenue growth remains positive but is materially slower than in earlier high-growth years. Sustained deceleration could limit operating leverage, reduce the pace of customer and market expansion, and make future earnings improvement more dependent on efficiency gains rather than broadening demand.
Modest EBIT ProfitabilityThe relatively low EBIT margin shows that substantial costs remain between EBITDA and operating profit, leaving limited cushion if expenses rise or growth weakens. This can constrain the durability of reported profitability and makes execution on cost control important for converting software revenue into stronger operating returns.
Uneven Free Cash Flow ConversionAlthough cash generation has improved, the uneven history and FCF below net income indicate that earnings are not yet converting consistently into cash. Working-capital or investment demands may continue to absorb resources, limiting the reliability of internally generated funds for growth and capital allocation.
Carasent AB News
CARA FAQ
What was Carasent AB’s price range in the past 12 months?
Carasent AB lowest stock price was kr21.70 and its highest was kr29.45 in the past 12 months.
What is Carasent AB’s market cap?
Carasent AB’s market cap is kr1.79B.
When is Carasent AB’s upcoming earnings report date?
Carasent AB’s upcoming earnings report date is Oct 15, 2026 which is in 23 days.
How were Carasent AB’s earnings last quarter?
Carasent AB released its earnings results on Jul 10, 2026. The company reported -kr0.04 earnings per share for the quarter, missing the consensus estimate of kr0.023 by -kr0.063.
Is Carasent AB overvalued?
According to Wall Street analysts Carasent AB’s price is currently Overvalued.
Does Carasent AB pay dividends?
Carasent AB pays a Notavailable dividend of kr1.84 which represents an annual dividend yield of 15.83%. See more information on Carasent AB dividends here
What is Carasent AB’s EPS estimate?
Carasent AB’s EPS estimate is 0.13.
How many shares outstanding does Carasent AB have?
Carasent AB has 70,324,780 shares outstanding.
What happened to Carasent AB’s price movement after its last earnings report?
Carasent AB reported an EPS of -kr0.04 in its last earnings report, missing expectations of kr0.023. Following the earnings report the stock price went up 7.253%.
Which hedge fund is a major shareholder of Carasent AB?
Currently, no hedge funds are holding shares in SE:CARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Carasent AB
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.
Technical Analysis
24SevenOffice
―
Lime Technologies AB
―
Vitec Software Group AB Class B
―
Upsales Technology AB
―
Oneflow AB
―